Adherence to endocrine therapy and its relation to disease‐free survival among breast cancer patients visiting an out‐patient clinic at Khartoum Oncology Hospital, Sudan
Rationale Adherence to endocrine therapy provides substantial reduction in breast cancer (BC) relapses and improve survival. Hence, non‐adherence remains an under reported issue mainly in developing countries. Aims and Objectives The aim of this study is to evaluate the adherence to endocrine therap...
Gespeichert in:
| Veröffentlicht in: | Journal of evaluation in clinical practice 2020-12, Vol.26 (6), p.1731-1743 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1743 |
|---|---|
| container_issue | 6 |
| container_start_page | 1731 |
| container_title | Journal of evaluation in clinical practice |
| container_volume | 26 |
| creator | Mohamed, Kamal E. H. Elamin, Amany |
| description | Rationale
Adherence to endocrine therapy provides substantial reduction in breast cancer (BC) relapses and improve survival. Hence, non‐adherence remains an under reported issue mainly in developing countries.
Aims and Objectives
The aim of this study is to evaluate the adherence to endocrine therapy (tamoxifen [TAM] and aromatase inhibitors [AIs]) among BC patients visiting an out‐patient clinic (2015‐2016) in Khartoum Oncology Hospital, Sudan.
Methods
Adherence was assessed using pills count and self‐reporting methods. A total of 172 patients were interviewed. Also, records were reviewed for demographic and other cancer characteristics.
Results
The patients' mean age at diagnosis was 53 years, with the highest frequency at (41‐60) years. Invasive ductal carcinoma 69.2% formed the main pathological diagnosis. T2 tumour size (51.2%) and lymph node involvement (N1) (31.4%) were most evident. Also, the majority of patients were stage III (45.9%) and grade II (48%). The studied women were postmenopausal (49.4%) and premenopausal (47.7%). Regarding hormonal receptors, about 68% were oestrogen (ER)+/progesterone (PR)+ and 23.3% were ER+/PR−. Studying adherence, almost (93%) of the studied group were ≥80% adherent to TAM and AIs. The hormonal therapy persistence mean was 27.2 ± 22.5 months (40‐96). While adherence percentage mean was 93.7 ± 13.6% (0%‐100%). Also disease‐free survival (DFS) mean was 36.3 ± 32.7 months (4‐312). Adherence to hormonal therapy and persistence were significantly correlated (P < .000). Also, statistically significant association was found between hormonal therapy adherence (≥80%) and patient poor to average economic status (P = .006), and the marital status “married” (P = .008).
Conclusions
A high rate of adherence (93%) to endocrine therapy was estimated in the present study. Also, a positive association was found between the hormonal therapy persistence, and the DFS year's groups (P = .000), and the hormonal therapy types (P = .000). Adherence to hormonal therapy and persistence were significantly correlated (P < .000). |
| doi_str_mv | 10.1111/jep.13373 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2366640716</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2459879403</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-c064debf8e8df3e5b9fd11b2e13add167d9a0205794408b51a175cea8d3a05833</originalsourceid><addsrcrecordid>eNp1kU9u1DAUhyMEoqWw4ALIEhuQmtaOEydZVlVLgUpFAtbWi_3SeuTYwXYGza5H4CJcipPUwwwskPDGf973Plv-FcVLRk9YHqcrnE8Y5y1_VBwyLpqyahv-eLtuRMmqvj4onsW4opRx2rRPiwNeMcpEXR8WP8_0HQZ0CknyBJ32KhiXN_kU5g0Bp4lJkQS0kIx3W0qbiBDx1_2PMSCSuIS1WYMlMHl3S4aQi4koyM5A5tyFLgvWJppkch0c8UvKzfsSUdY4owgk8vEOQvLLRG6c8tbfbsiVj7NJYI_J50WDe148GcFGfLGfj4qvlxdfzq_K65t378_PrkvFu46Xiopa4zB22OmRYzP0o2ZsqJBx0JqJVvdAq_wVfV3TbmgYsLZRCJ3mQJuO86Pizc47B_9twZjkZKJCa8GhX6KsuBCipi0TGX39D7ryS3D5dbKqm77Ld9Ct8O2OUsHHGHCUczAThI1kVG4zlDlD-TvDzL7aG5dhQv2X_BNaBk53wHdjcfN_k_xw8WmnfAC4_Krg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2459879403</pqid></control><display><type>article</type><title>Adherence to endocrine therapy and its relation to disease‐free survival among breast cancer patients visiting an out‐patient clinic at Khartoum Oncology Hospital, Sudan</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Mohamed, Kamal E. H. ; Elamin, Amany</creator><creatorcontrib>Mohamed, Kamal E. H. ; Elamin, Amany</creatorcontrib><description>Rationale
Adherence to endocrine therapy provides substantial reduction in breast cancer (BC) relapses and improve survival. Hence, non‐adherence remains an under reported issue mainly in developing countries.
Aims and Objectives
The aim of this study is to evaluate the adherence to endocrine therapy (tamoxifen [TAM] and aromatase inhibitors [AIs]) among BC patients visiting an out‐patient clinic (2015‐2016) in Khartoum Oncology Hospital, Sudan.
Methods
Adherence was assessed using pills count and self‐reporting methods. A total of 172 patients were interviewed. Also, records were reviewed for demographic and other cancer characteristics.
Results
The patients' mean age at diagnosis was 53 years, with the highest frequency at (41‐60) years. Invasive ductal carcinoma 69.2% formed the main pathological diagnosis. T2 tumour size (51.2%) and lymph node involvement (N1) (31.4%) were most evident. Also, the majority of patients were stage III (45.9%) and grade II (48%). The studied women were postmenopausal (49.4%) and premenopausal (47.7%). Regarding hormonal receptors, about 68% were oestrogen (ER)+/progesterone (PR)+ and 23.3% were ER+/PR−. Studying adherence, almost (93%) of the studied group were ≥80% adherent to TAM and AIs. The hormonal therapy persistence mean was 27.2 ± 22.5 months (40‐96). While adherence percentage mean was 93.7 ± 13.6% (0%‐100%). Also disease‐free survival (DFS) mean was 36.3 ± 32.7 months (4‐312). Adherence to hormonal therapy and persistence were significantly correlated (P < .000). Also, statistically significant association was found between hormonal therapy adherence (≥80%) and patient poor to average economic status (P = .006), and the marital status “married” (P = .008).
Conclusions
A high rate of adherence (93%) to endocrine therapy was estimated in the present study. Also, a positive association was found between the hormonal therapy persistence, and the DFS year's groups (P = .000), and the hormonal therapy types (P = .000). Adherence to hormonal therapy and persistence were significantly correlated (P < .000).</description><identifier>ISSN: 1356-1294</identifier><identifier>EISSN: 1365-2753</identifier><identifier>DOI: 10.1111/jep.13373</identifier><identifier>PMID: 32101644</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Inc</publisher><subject>adjuvant hormonal therapy ; Breast cancer ; Endocrine therapy ; Patient compliance ; Patients ; Sub‐Saharan Africa ; Sudan ; tamoxifen</subject><ispartof>Journal of evaluation in clinical practice, 2020-12, Vol.26 (6), p.1731-1743</ispartof><rights>2020 The Authors. published by John Wiley & Sons Ltd</rights><rights>2020 The Authors. Journal of Evaluation in Clinical Practice published by John Wiley & Sons Ltd.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-c064debf8e8df3e5b9fd11b2e13add167d9a0205794408b51a175cea8d3a05833</citedby><cites>FETCH-LOGICAL-c3883-c064debf8e8df3e5b9fd11b2e13add167d9a0205794408b51a175cea8d3a05833</cites><orcidid>0000-0002-3523-8276</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjep.13373$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjep.13373$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32101644$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohamed, Kamal E. H.</creatorcontrib><creatorcontrib>Elamin, Amany</creatorcontrib><title>Adherence to endocrine therapy and its relation to disease‐free survival among breast cancer patients visiting an out‐patient clinic at Khartoum Oncology Hospital, Sudan</title><title>Journal of evaluation in clinical practice</title><addtitle>J Eval Clin Pract</addtitle><description>Rationale
Adherence to endocrine therapy provides substantial reduction in breast cancer (BC) relapses and improve survival. Hence, non‐adherence remains an under reported issue mainly in developing countries.
Aims and Objectives
The aim of this study is to evaluate the adherence to endocrine therapy (tamoxifen [TAM] and aromatase inhibitors [AIs]) among BC patients visiting an out‐patient clinic (2015‐2016) in Khartoum Oncology Hospital, Sudan.
Methods
Adherence was assessed using pills count and self‐reporting methods. A total of 172 patients were interviewed. Also, records were reviewed for demographic and other cancer characteristics.
Results
The patients' mean age at diagnosis was 53 years, with the highest frequency at (41‐60) years. Invasive ductal carcinoma 69.2% formed the main pathological diagnosis. T2 tumour size (51.2%) and lymph node involvement (N1) (31.4%) were most evident. Also, the majority of patients were stage III (45.9%) and grade II (48%). The studied women were postmenopausal (49.4%) and premenopausal (47.7%). Regarding hormonal receptors, about 68% were oestrogen (ER)+/progesterone (PR)+ and 23.3% were ER+/PR−. Studying adherence, almost (93%) of the studied group were ≥80% adherent to TAM and AIs. The hormonal therapy persistence mean was 27.2 ± 22.5 months (40‐96). While adherence percentage mean was 93.7 ± 13.6% (0%‐100%). Also disease‐free survival (DFS) mean was 36.3 ± 32.7 months (4‐312). Adherence to hormonal therapy and persistence were significantly correlated (P < .000). Also, statistically significant association was found between hormonal therapy adherence (≥80%) and patient poor to average economic status (P = .006), and the marital status “married” (P = .008).
Conclusions
A high rate of adherence (93%) to endocrine therapy was estimated in the present study. Also, a positive association was found between the hormonal therapy persistence, and the DFS year's groups (P = .000), and the hormonal therapy types (P = .000). Adherence to hormonal therapy and persistence were significantly correlated (P < .000).</description><subject>adjuvant hormonal therapy</subject><subject>Breast cancer</subject><subject>Endocrine therapy</subject><subject>Patient compliance</subject><subject>Patients</subject><subject>Sub‐Saharan Africa</subject><subject>Sudan</subject><subject>tamoxifen</subject><issn>1356-1294</issn><issn>1365-2753</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kU9u1DAUhyMEoqWw4ALIEhuQmtaOEydZVlVLgUpFAtbWi_3SeuTYwXYGza5H4CJcipPUwwwskPDGf973Plv-FcVLRk9YHqcrnE8Y5y1_VBwyLpqyahv-eLtuRMmqvj4onsW4opRx2rRPiwNeMcpEXR8WP8_0HQZ0CknyBJ32KhiXN_kU5g0Bp4lJkQS0kIx3W0qbiBDx1_2PMSCSuIS1WYMlMHl3S4aQi4koyM5A5tyFLgvWJppkch0c8UvKzfsSUdY4owgk8vEOQvLLRG6c8tbfbsiVj7NJYI_J50WDe148GcFGfLGfj4qvlxdfzq_K65t378_PrkvFu46Xiopa4zB22OmRYzP0o2ZsqJBx0JqJVvdAq_wVfV3TbmgYsLZRCJ3mQJuO86Pizc47B_9twZjkZKJCa8GhX6KsuBCipi0TGX39D7ryS3D5dbKqm77Ld9Ct8O2OUsHHGHCUczAThI1kVG4zlDlD-TvDzL7aG5dhQv2X_BNaBk53wHdjcfN_k_xw8WmnfAC4_Krg</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Mohamed, Kamal E. H.</creator><creator>Elamin, Amany</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3523-8276</orcidid></search><sort><creationdate>202012</creationdate><title>Adherence to endocrine therapy and its relation to disease‐free survival among breast cancer patients visiting an out‐patient clinic at Khartoum Oncology Hospital, Sudan</title><author>Mohamed, Kamal E. H. ; Elamin, Amany</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-c064debf8e8df3e5b9fd11b2e13add167d9a0205794408b51a175cea8d3a05833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>adjuvant hormonal therapy</topic><topic>Breast cancer</topic><topic>Endocrine therapy</topic><topic>Patient compliance</topic><topic>Patients</topic><topic>Sub‐Saharan Africa</topic><topic>Sudan</topic><topic>tamoxifen</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohamed, Kamal E. H.</creatorcontrib><creatorcontrib>Elamin, Amany</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of evaluation in clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohamed, Kamal E. H.</au><au>Elamin, Amany</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adherence to endocrine therapy and its relation to disease‐free survival among breast cancer patients visiting an out‐patient clinic at Khartoum Oncology Hospital, Sudan</atitle><jtitle>Journal of evaluation in clinical practice</jtitle><addtitle>J Eval Clin Pract</addtitle><date>2020-12</date><risdate>2020</risdate><volume>26</volume><issue>6</issue><spage>1731</spage><epage>1743</epage><pages>1731-1743</pages><issn>1356-1294</issn><eissn>1365-2753</eissn><abstract>Rationale
Adherence to endocrine therapy provides substantial reduction in breast cancer (BC) relapses and improve survival. Hence, non‐adherence remains an under reported issue mainly in developing countries.
Aims and Objectives
The aim of this study is to evaluate the adherence to endocrine therapy (tamoxifen [TAM] and aromatase inhibitors [AIs]) among BC patients visiting an out‐patient clinic (2015‐2016) in Khartoum Oncology Hospital, Sudan.
Methods
Adherence was assessed using pills count and self‐reporting methods. A total of 172 patients were interviewed. Also, records were reviewed for demographic and other cancer characteristics.
Results
The patients' mean age at diagnosis was 53 years, with the highest frequency at (41‐60) years. Invasive ductal carcinoma 69.2% formed the main pathological diagnosis. T2 tumour size (51.2%) and lymph node involvement (N1) (31.4%) were most evident. Also, the majority of patients were stage III (45.9%) and grade II (48%). The studied women were postmenopausal (49.4%) and premenopausal (47.7%). Regarding hormonal receptors, about 68% were oestrogen (ER)+/progesterone (PR)+ and 23.3% were ER+/PR−. Studying adherence, almost (93%) of the studied group were ≥80% adherent to TAM and AIs. The hormonal therapy persistence mean was 27.2 ± 22.5 months (40‐96). While adherence percentage mean was 93.7 ± 13.6% (0%‐100%). Also disease‐free survival (DFS) mean was 36.3 ± 32.7 months (4‐312). Adherence to hormonal therapy and persistence were significantly correlated (P < .000). Also, statistically significant association was found between hormonal therapy adherence (≥80%) and patient poor to average economic status (P = .006), and the marital status “married” (P = .008).
Conclusions
A high rate of adherence (93%) to endocrine therapy was estimated in the present study. Also, a positive association was found between the hormonal therapy persistence, and the DFS year's groups (P = .000), and the hormonal therapy types (P = .000). Adherence to hormonal therapy and persistence were significantly correlated (P < .000).</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Inc</pub><pmid>32101644</pmid><doi>10.1111/jep.13373</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-3523-8276</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1356-1294 |
| ispartof | Journal of evaluation in clinical practice, 2020-12, Vol.26 (6), p.1731-1743 |
| issn | 1356-1294 1365-2753 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2366640716 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | adjuvant hormonal therapy Breast cancer Endocrine therapy Patient compliance Patients Sub‐Saharan Africa Sudan tamoxifen |
| title | Adherence to endocrine therapy and its relation to disease‐free survival among breast cancer patients visiting an out‐patient clinic at Khartoum Oncology Hospital, Sudan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T07%3A01%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adherence%20to%20endocrine%20therapy%20and%20its%20relation%20to%20disease%E2%80%90free%20survival%20among%20breast%20cancer%20patients%20visiting%20an%20out%E2%80%90patient%20clinic%20at%20Khartoum%20Oncology%20Hospital,%20Sudan&rft.jtitle=Journal%20of%20evaluation%20in%20clinical%20practice&rft.au=Mohamed,%20Kamal%20E.%20H.&rft.date=2020-12&rft.volume=26&rft.issue=6&rft.spage=1731&rft.epage=1743&rft.pages=1731-1743&rft.issn=1356-1294&rft.eissn=1365-2753&rft_id=info:doi/10.1111/jep.13373&rft_dat=%3Cproquest_cross%3E2459879403%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2459879403&rft_id=info:pmid/32101644&rfr_iscdi=true |